PortfoliosLab logo
DRUG vs. ^GSPC
Performance
Risk-Adjusted Performance
Drawdowns
Volatility

Correlation

The correlation between DRUG and ^GSPC is 0.18, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.0
Correlation: 0.2

Performance

DRUG vs. ^GSPC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Bright Minds Biosciences Inc (DRUG) and S&P 500 (^GSPC). The values are adjusted to include any dividend payments, if applicable.

0.00%20.00%40.00%60.00%80.00%100.00%December2025FebruaryMarchAprilMay
13.41%
42.22%
DRUG
^GSPC

Key characteristics

Sharpe Ratio

DRUG:

1.87

^GSPC:

0.49

Sortino Ratio

DRUG:

25.59

^GSPC:

0.81

Omega Ratio

DRUG:

4.06

^GSPC:

1.12

Calmar Ratio

DRUG:

27.87

^GSPC:

0.50

Martin Ratio

DRUG:

104.66

^GSPC:

2.00

Ulcer Index

DRUG:

26.01%

^GSPC:

4.76%

Daily Std Dev

DRUG:

1,461.48%

^GSPC:

19.36%

Max Drawdown

DRUG:

-97.67%

^GSPC:

-56.78%

Current Drawdown

DRUG:

-45.10%

^GSPC:

-8.79%

Returns By Period

In the year-to-date period, DRUG achieves a -14.99% return, which is significantly lower than ^GSPC's -4.72% return.


DRUG

YTD

-14.99%

1M

-15.20%

6M

-34.57%

1Y

2,844.23%

5Y*

N/A

10Y*

N/A

^GSPC

YTD

-4.72%

1M

-0.51%

6M

-1.78%

1Y

11.67%

5Y*

14.69%

10Y*

10.26%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

DRUG vs. ^GSPC — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DRUG
The Risk-Adjusted Performance Rank of DRUG is 9999
Overall Rank
The Sharpe Ratio Rank of DRUG is 9595
Sharpe Ratio Rank
The Sortino Ratio Rank of DRUG is 100100
Sortino Ratio Rank
The Omega Ratio Rank of DRUG is 100100
Omega Ratio Rank
The Calmar Ratio Rank of DRUG is 100100
Calmar Ratio Rank
The Martin Ratio Rank of DRUG is 100100
Martin Ratio Rank

^GSPC
The Risk-Adjusted Performance Rank of ^GSPC is 7070
Overall Rank
The Sharpe Ratio Rank of ^GSPC is 6969
Sharpe Ratio Rank
The Sortino Ratio Rank of ^GSPC is 6666
Sortino Ratio Rank
The Omega Ratio Rank of ^GSPC is 7171
Omega Ratio Rank
The Calmar Ratio Rank of ^GSPC is 7171
Calmar Ratio Rank
The Martin Ratio Rank of ^GSPC is 7575
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

DRUG vs. ^GSPC - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Bright Minds Biosciences Inc (DRUG) and S&P 500 (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The chart of Sharpe ratio for DRUG, currently valued at 1.87, compared to the broader market-2.00-1.000.001.002.003.00
DRUG: 1.87
^GSPC: 0.49
The chart of Sortino ratio for DRUG, currently valued at 25.59, compared to the broader market-6.00-4.00-2.000.002.004.00
DRUG: 25.59
^GSPC: 0.81
The chart of Omega ratio for DRUG, currently valued at 4.06, compared to the broader market0.501.001.502.00
DRUG: 4.06
^GSPC: 1.12
The chart of Calmar ratio for DRUG, currently valued at 27.87, compared to the broader market0.001.002.003.004.005.00
DRUG: 27.87
^GSPC: 0.50
The chart of Martin ratio for DRUG, currently valued at 104.66, compared to the broader market-10.000.0010.0020.00
DRUG: 104.66
^GSPC: 2.00

The current DRUG Sharpe Ratio is 1.87, which is higher than the ^GSPC Sharpe Ratio of 0.49. The chart below compares the historical Sharpe Ratios of DRUG and ^GSPC, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.001.002.003.00December2025FebruaryMarchAprilMay
1.87
0.49
DRUG
^GSPC

Drawdowns

DRUG vs. ^GSPC - Drawdown Comparison

The maximum DRUG drawdown since its inception was -97.67%, which is greater than ^GSPC's maximum drawdown of -56.78%. Use the drawdown chart below to compare losses from any high point for DRUG and ^GSPC. For additional features, visit the drawdowns tool.


-50.00%-40.00%-30.00%-20.00%-10.00%0.00%December2025FebruaryMarchAprilMay
-45.10%
-8.79%
DRUG
^GSPC

Volatility

DRUG vs. ^GSPC - Volatility Comparison

Bright Minds Biosciences Inc (DRUG) has a higher volatility of 21.59% compared to S&P 500 (^GSPC) at 14.11%. This indicates that DRUG's price experiences larger fluctuations and is considered to be riskier than ^GSPC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%50.00%100.00%150.00%200.00%250.00%300.00%December2025FebruaryMarchAprilMay
21.59%
14.11%
DRUG
^GSPC